These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8843484)

  • 1. Research strategies to assess pharmacotherapies for alcoholism.
    Naranjo CA; Bremner KE; Poulos CX
    Prog Neuropsychopharmacol Biol Psychiatry; 1996 May; 20(4):543-59. PubMed ID: 8843484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological treatment of alcohol dependence: a review of the evidence.
    Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT
    JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoxetine attenuates alcohol intake and desire to drink.
    Naranjo CA; Poulos CX; Bremner KE; Lanctot KL
    Int Clin Psychopharmacol; 1994 Sep; 9(3):163-72. PubMed ID: 7814825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ritanserin, a central 5-HT2 antagonist, in heavy social drinkers: desire to drink, alcohol intake and related effects.
    Naranjo CA; Poulos CX; Lanctôt KL; Bremner KE; Kwok M; Umana M
    Addiction; 1995 Jul; 90(7):893-905. PubMed ID: 7663312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rational approach to the pharmacotherapy of alcohol dependence.
    Petrakis IL
    J Clin Psychopharmacol; 2006 Dec; 26 Suppl 1():S3-12. PubMed ID: 17114952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.
    Wilde MI; Wagstaff AJ
    Drugs; 1997 Jun; 53(6):1038-53. PubMed ID: 9179530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption.
    Aubin HJ; Daeppen JB
    Drug Alcohol Depend; 2013 Nov; 133(1):15-29. PubMed ID: 23746430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study.
    Soyka M; Preuss U; Schuetz C
    Drugs R D; 2002; 3(1):1-12. PubMed ID: 11881521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical and clinical pharmacology of alcohol dependence.
    Tambour S; Quertemont E
    Fundam Clin Pharmacol; 2007 Feb; 21(1):9-28. PubMed ID: 17227441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.
    Witkiewitz K; Pearson MR; Hallgren KA; Maisto SA; Roos CR; Kirouac M; Wilson AD; Montes KS; Heather N
    Addiction; 2017 Dec; 112(12):2112-2121. PubMed ID: 28511286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research.
    Kranzler HR
    Alcohol Alcohol; 2000; 35(6):537-47. PubMed ID: 11093959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacological treatment of alcohol dependence: needs and possibilities.
    Mann K
    Alcohol Alcohol Suppl; 1996 Mar; 31(1):55-8. PubMed ID: 9845038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GRIK1 genotype and daily expectations of alcohol's positive effects moderate the reduction of heavy drinking by topiramate.
    Kranzler HR; Armeli S; Tennen H; Gelernter J; Covault J
    Exp Clin Psychopharmacol; 2014 Dec; 22(6):494-501. PubMed ID: 25436841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining psychosocial treatment with pharmacotherapy for alcohol dependence.
    Weiss RD; Kueppenbender KD
    J Clin Psychopharmacol; 2006 Dec; 26 Suppl 1():S37-42. PubMed ID: 17114954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ritanserin and alcohol abuse and dependence.
    Meert TF
    Alcohol Alcohol Suppl; 1994; 2():523-30. PubMed ID: 8974378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommended drug treatment strategies for the alcoholic patient.
    Schaffer A; Naranjo CA
    Drugs; 1998 Oct; 56(4):571-85. PubMed ID: 9806104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of serotonin (5-hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism.
    Lejoyeux M
    Alcohol Alcohol Suppl; 1996 Mar; 31(1):69-75. PubMed ID: 9845041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapies for alcoholism: promising agents and clinical issues.
    Litten RZ; Allen JP
    Alcohol Clin Exp Res; 1991 Aug; 15(4):620-33. PubMed ID: 1928636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers.
    Naranjo CA; Poulos CX; Bremner KE; Lanctôt KL
    Clin Pharmacol Ther; 1992 Jun; 51(6):729-39. PubMed ID: 1535302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy of alcohol dependence: past, present and future research.
    Leggio L; Addolorato G
    Curr Pharm Des; 2010; 16(19):2074-5. PubMed ID: 20482504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.